Assuta - University Hospital
Welcome,         Profile    Billing    Logout  
 0 Trials 
1 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Brosh, Tal
NCT04608305: Evaluate the Safety, Immunogenicity and Potential Efficacy of an rVSV-SARS-CoV-2-S Vaccine

Completed
1/2
843
RoW
IIBR-100, low dose (prime), IIBR-100 medium dose (prime), IIBR-100 high-dose (prime), IIBR-100 low-dose (prime-boost), Saline Placebo (single), Saline Placebo (double), IIBR-100 medium-dose (prime-boost), IIBR-100 high-dose (prime-boost), IIBR-100 top-dose (prime-boost)
Israel Institute for Biological Research (IIBR)
Covid19
10/22
10/22
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Brosh, Tal
NCT04608305: Evaluate the Safety, Immunogenicity and Potential Efficacy of an rVSV-SARS-CoV-2-S Vaccine

Completed
1/2
843
RoW
IIBR-100, low dose (prime), IIBR-100 medium dose (prime), IIBR-100 high-dose (prime), IIBR-100 low-dose (prime-boost), Saline Placebo (single), Saline Placebo (double), IIBR-100 medium-dose (prime-boost), IIBR-100 high-dose (prime-boost), IIBR-100 top-dose (prime-boost)
Israel Institute for Biological Research (IIBR)
Covid19
10/22
10/22

Download Options